Valsartan

Hypesthesia, Hypesthesia, Hypesthesia + 15 more
Treatment
11 FDA approvals
20 Active Studies for Valsartan

What is Valsartan

ValsartanThe Generic name of this drug
Treatment SummaryValsartan is a medication used to treat high blood pressure, heart failure, and kidney damage caused by diabetes. It is part of the angiotensin II receptor blocker (ARB) family of drugs, which works by blocking the activity of a protein called angiotensin II. This protein causes blood vessels to narrow, leading to higher blood pressure. By blocking its activity, valsartan helps lower blood pressure and reduce the risk of heart attack and stroke. It is usually well tolerated and has a lower risk for side effects compared to other antihypertensive drugs. Valsartan was approved in 1996 in Europe
Diovanis the brand name
image of different drug pills on a surface
Valsartan Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Diovan
Valsartan
1996
621

Approved as Treatment by the FDA

Valsartan, also known as Diovan, is approved by the FDA for 11 uses such as Heart failure and Heart Failure .
Heart failure
Used to treat Heart Failure in combination with Sacubitril
Heart Failure
Used to treat hospitalization due to cardiac failure in combination with Sacubitril
Systolic Left Ventricular Dysfunction
Used to treat Systolic Left Ventricular Dysfunction in combination with Sacubitril
High Blood Pressure
Used to treat Moderate Essential Hypertension in combination with Hydrochlorothiazide
Combined Modality Therapy
Used to treat patients for whom combination therapy is appropriate in combination with Hydrochlorothiazide
chronic heart failure with reduced ejection fraction (NYHA Class II-IV)
Used to treat chronic heart failure with reduced ejection fraction (NYHA Class II-IV) in combination with Sacubitril
Cardiovascular Mortality
Used to treat Cardiovascular Mortality in combination with Sacubitril
Moderate Essential Hypertension
Used to treat Moderate Essential Hypertension in combination with Hydrochlorothiazide
Hypesthesia
Used to treat chronic heart failure with reduced ejection fraction (NYHA Class II-IV) in combination with Sacubitril
Congestive Heart Failure
Used to treat Heart Failure in combination with Sacubitril
Ventricular Dysfunction, Left
Used to treat Systolic Left Ventricular Dysfunction in combination with Sacubitril

Effectiveness

How Valsartan Affects PatientsValsartan helps to control blood pressure by blocking the effects of a hormone (angiotensin II). It usually takes an oral dose of 80mg to reduce blood pressure by around 80%. The use of valsartan can lead to a slight decrease in cholesterol, triglycerides, glucose, and uric acid. Low blood pressure can be a side effect of valsartan, especially in patients who are already low in salt or taking high doses of diuretics. People with heart failure may also experience low blood pressure when taking valsartan, but usually it is not severe. If low blood pressure does occur
How Valsartan works in the bodyValsartan is a drug that belongs to a family of medications called angiotensin II receptor blockers (ARBs). It works by blocking the receptor that angiotensin II binds to in order to control blood pressure and reduce inflammation. This helps to lower the amount of stress on the heart, improve cardiac function, and reduce the chances of a heart attack or stroke. Valsartan is used to treat high blood pressure, heart failure, and complications related to diabetes and kidney disease. It can also be used to slow the progression of kidney disease. Valsartan has a much higher affinity for the AT1 receptor

When to interrupt dosage

The prescribed measure of Valsartan is contingent upon the determined illness, such as initial treatment, Left Ventricular Failure, Unspecified and Combined Modality Therapy. The amount of dosage is contingent upon the method of delivery (e.g. Tablet - Oral or Tablet, film coated) featured in the table beneath.
Condition
Dosage
Administration
Hypesthesia
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
Hypesthesia
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
Hypesthesia
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
Hypesthesia
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
Diabetic Nephropathies
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
Congestive Heart Failure
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
Type 2 Diabetes
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
High Blood Pressure
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
Cardiovascular Mortality
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
Hypertensive disease
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
Combined Modality Therapy
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
initial treatment
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
multiple antihypertensive drugs likely required
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
not adequately controlled with monotherapy
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
Ventricular Dysfunction, Left
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
Left Ventricular Failure, Unspecified
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
Ventricular Dysfunction, Left
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral
Heart Failure
160.0 mg, 320.0 mg, , 80.0 mg, 40.0 mg, 1.6 mg, 3.2 mg, 26.0 mg, 51.0 mg, 103.0 mg, 4.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral

Warnings

Valsartan Contraindications
Condition
Risk Level
Notes
Type 2 Diabetes
Do Not Combine
Breast Milk Production
Do Not Combine
Diabetes
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Valsartan may interact with Pulse Frequency
There are 20 known major drug interactions with Valsartan.
Common Valsartan Drug Interactions
Drug Name
Risk Level
Description
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Valsartan.
Amifostine
Major
Valsartan may increase the hypotensive activities of Amifostine.
Cabozantinib
Major
The metabolism of Cabozantinib can be decreased when combined with Valsartan.
Capecitabine
Major
The metabolism of Capecitabine can be decreased when combined with Valsartan.
Cyclophosphamide
Major
The metabolism of Cyclophosphamide can be decreased when combined with Valsartan.
Valsartan Toxicity & Overdose RiskThe highest dose of valsartan that is considered toxic to rats is greater than 2000mg/kg. Studies on pregnant mice, rats, and rabbits showed no evidence of birth defects, but there were decreases in fetal weight, pup birth weight, pup survival rate, and delays in developmental milestones when the mother was given a maternally toxic dose of valsartan (600mg/kg/day) during organogenesis or late gestation and lactation. If pregnancy is detected while taking valsartan, it should be stopped as soon as possible.
image of a doctor in a lab doing drug, clinical research

Valsartan Novel Uses: Which Conditions Have a Clinical Trial Featuring Valsartan?

510 active clinical trials are presently investigating the potential of Valsartan to ameliorate Type 2 Diabetes, Diabetic Nephropathy and Hypertension.
Condition
Clinical Trials
Trial Phases
Diabetic Nephropathies
0 Actively Recruiting
High Blood Pressure
7 Actively Recruiting
Not Applicable, Early Phase 1, Phase 3
Hypesthesia
4 Actively Recruiting
Not Applicable, Phase 1
Ventricular Dysfunction, Left
3 Actively Recruiting
Phase 2, Phase 3
Type 2 Diabetes
165 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Congestive Heart Failure
184 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1
Hypesthesia
2 Actively Recruiting
Not Applicable
Cardiovascular Mortality
0 Actively Recruiting
Hypertensive disease
27 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Ventricular Dysfunction, Left
0 Actively Recruiting
Combined Modality Therapy
0 Actively Recruiting
Heart Failure
0 Actively Recruiting
Left Ventricular Failure, Unspecified
0 Actively Recruiting
Hypesthesia
0 Actively Recruiting
not adequately controlled with monotherapy
0 Actively Recruiting
Hypesthesia
8 Actively Recruiting
Not Applicable, Phase 1
initial treatment
0 Actively Recruiting
multiple antihypertensive drugs likely required
0 Actively Recruiting

Valsartan Reviews: What are patients saying about Valsartan?

5Patient Review
11/29/2017
Valsartan for High Blood Pressure
4Patient Review
1/3/2018
Valsartan for High Blood Pressure
3.7Patient Review
5/12/2018
Valsartan for High Blood Pressure
I felt like I was retaining water after taking valssrtan. Within two weeks, I had gained ten pounds and experienced extreme headaches and swollen fingers. After stopping the medication cold turkey, I contacted my doctor. Additionally, while on the medication I would feel short of breath and experience weakness in my arms and hips.
3.7Patient Review
9/4/2019
Valsartan for High Blood Pressure
Although I generally had good outcomes, I was worried about the amount of weight gain.
3Patient Review
9/21/2019
Valsartan for High Blood Pressure
This medication led to a loss of control over my bladder and bowels. I would have to get up multiple times per night, and even after discontinuing the medication, I still experience these effects albeit less frequently.
3Patient Review
4/17/2018
Valsartan for Heart Failure
This medication has been successful in keeping my blood pressure at a healthy level for the past year. I have experienced no negative side effects and am overall very satisfied with it.
3Patient Review
9/8/2018
Valsartan for High Blood Pressure
This medication did not help to control my blood pressure at all. If anything, it made it more erratic.
2.7Patient Review
3/6/2022
Valsartan for High Blood Pressure
After just ten days of use, I experienced shortness of breath, blurred vision, and pain in my left side. Additionally, brain fog made me feel forgetful and off balance.
2.7Patient Review
6/2/2022
Valsartan for Kidney Disease from Diabetes
This lowered my blood pressure but unfortunately also came with a host of nasty side effects, like body aches and an upset stomach. I had to switch to losartan 50 mg after only taking valsartan 120 mg for one month.
1.7Patient Review
2/8/2019
Valsartan for High Blood Pressure
I was prescribed this medication for high blood pressure, but it didn't work at all. My pressure remained the same after one week of use. I'm now looking for a new physician.
1.7Patient Review
3/23/2022
Valsartan for High Blood Pressure
While this medication does help to lower my blood pressure, the side effects are very difficult to deal with. I suffer from fatigue, insomnia, lack of concentration, and leg pain (among other things) as a result of taking this medication. Last night, I skipped taking it and was able to sleep just fine--so I'm hoping my doctor will be willing to make a change.
1.7Patient Review
5/17/2022
Valsartan for High Blood Pressure
I stopped taking Valsartan a week ago and I feel SO much better. Dizziness was a big problem for me before, but it's gone now and I feel like a new person.
1Patient Review
7/17/2018
Valsartan for High Blood Pressure
I am a 78-year-old woman with high blood pressure. This medication was very effective at reducing my BP, but I experienced daily back pain as a result. I will be getting off of it when a good replacement can be found.
1Patient Review
12/25/2019
Valsartan for High Blood Pressure
I started experiencing pain after only two months of taking this medication. Additionally, I had an episode where my heart gave me a hard shock and I lost my breath. I was unable to move for about ten minutes. Once I was able to regain movement, I sought medical help and discontinue the use of this drug.
1Patient Review
4/6/2018
Valsartan for High Blood Pressure
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about valsartan

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of drug is valsartan?

"Valsartan is a drug that helps to lower blood pressure by blocking the tightening of blood vessels. This increased blood flow and oxygen to the heart."

Answered by AI

What should you not take with valsartan?

"Some drugs may interact with Tadalafil resulting in reduced effectiveness or increased side effects. These are:

-Certain diuretics -Ritonavir -Cyclosporine -Rifampin -Nonsteroidal anti-inflammatory drugs such as aspirin, ibuprofen, naproxen, celecoxib, diclofenac, indomethacin or meloxicam"

Answered by AI

What are side effects of valsartan?

"The following are symptoms of kidney failure: bloody urine, decreased frequency or amount of urine, difficult breathing, dizziness, faintness, or lightheadedness when getting up from a lying position, increased thirst, irregular heartbeat, numbness or tingling in the hands, feet, or lips, swelling of the face, fingers, or lower legs."

Answered by AI

What is the best time to take valsartan?

"Most people will take valsartan once or twice per day. The recommended time to take the first dose is before bedtime, as it can cause dizziness. After the first dose, valsartan can be taken at any time, although it is best to take it at the same time each day."

Answered by AI

Clinical Trials for Valsartan

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL
This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.
Waitlist Available
Has No Placebo
U Health (+1 Sites)Ziad Zoghby, M.D., M.B.A.Biobeat Technologies Ltd.
Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Image of Medpace Clinical Pharmaology Unit in Cincinnati, United States.

PATAS for Type 2 Diabetes

18 - 55
All Sexes
Cincinnati, OH
The primary objective of Part 1 of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of Part 1 of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 of this study are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. The secondary objectives of Part 2 of this study are to evaluate the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers; and to characterize the adverse event (AE) profiles of the various dose levels of PATAS.
Phase 1
Waitlist Available
Medpace Clinical Pharmaology UnitVincent Marion, Ph.D.AdipoPharma LLC
Have you considered Valsartan clinical trials? We made a collection of clinical trials featuring Valsartan, we think they might fit your search criteria.Go to Trials
Image of The Worship Center Cristian Church in Birmingham, United States.

Black Impact for Heart Health

18+
Male
Birmingham, AL
The goal of this clinical trial is to evaluate the implementation and effectiveness of the Black Impact program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the Black Impact program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the Black Impact program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.
Waitlist Available
Has No Placebo
The Worship Center Cristian Church
Have you considered Valsartan clinical trials? We made a collection of clinical trials featuring Valsartan, we think they might fit your search criteria.Go to Trials
Image of Los Angeles General Medical Center in Los Angeles, United States.

Supportive Management for Heart Failure and Methamphetamine Addiction

18+
All Sexes
Los Angeles, CA
Heart failure (HF) affects over 6 million people in the US and is a major cause of both hospital admissions and death. HF has many causes and contributing factors. One of the most aggressive forms of HF is associated with methamphetamine abuse, which has become its own epidemic in the US over the past twenty years. People who use methamphetamine tend to develop HF at a much younger age, with more severe disease and more serious consequences. A recent analysis using nationwide data, methamphetamine use doubled the risk of death or hospitalizations compared to non-users in patients with HF. Thus, methamphetamine users with HF represent a very high-risk group of patients from a healthcare perspective. HF may be reversible in some patients who use methamphetamine if patients can achieve 1) abstain from further methamphetamine use and 2) consistently take all the medications that can improve HF. These two goals are very difficult to achieve in practice, as the care of both methamphetamine addiction and HF requires specialized medical expertise and intensive regular follow up of patients. In general, achievement of one goal is not possible without the other. Patients who use methamphetamine have poor adherence to medical follow-up and therapies, and abstinence from methamphetamine is difficult to maintain. This is further complicated because the current model of HF care does not incorporate treatment for methamphetamine use. The current study proposes to launch a multidisciplinary clinic that treats both HF and methamphetamine use disorder at the same time. The HF care will be led by a cardiologist while the methamphetamine use treatment will be led by a psychiatric clinical pharmacist trained in addiction medicine. State-of-the-art HF care will include optimization of four pillar HF medications. Methamphetamine use treatment will include counseling and incentivized abstinence known as contingency management (CM). The investigators will manage the patients in the clinic for 6 months total. The investigators are interested in demonstrating that this integrated clinic model will result in improved delivery of care for these patients by reporting the rates of successful abstinence from methamphetamine, improved optimization of the four HF medications, and enhanced patient reported quality of life over the 6 months of follow up. The investigators will also collect data on the costs associated with providing this level of care and estimate a range of potential cost-savings.
Waitlist Available
Has No Placebo
Los Angeles General Medical Center (+1 Sites)Tien Ng, PharmD
Have you considered Valsartan clinical trials? We made a collection of clinical trials featuring Valsartan, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security